NPI: 1922144757 · DUNN, NC 28334 · General Acute Care Hospital · NPI assigned 01/29/2007
Authorized official FISER, JOSEPH controls 20+ related entities in our dataset. Read more
| Authorized Official | FISER, JOSEPH (VP CORP REV CYCLE/MANAGED CARE) |
| Parent Organization | HARNETT HEALTH SYSTEM INC |
| NPI Enumeration Date | 01/29/2007 |
Other providers sharing the same authorized official: FISER, JOSEPH
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 116,198 | $2.69M |
| 2019 | 117,345 | $2.68M |
| 2020 | 72,508 | $1.83M |
| 2021 | 90,634 | $3.45M |
| 2022 | 99,369 | $4.58M |
| 2023 | 104,343 | $4.07M |
| 2024 | 97,937 | $4.08M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 59,316 | 53,560 | $7.54M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 24,331 | 21,128 | $4.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 39,419 | 36,192 | $2.77M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 11,892 | 10,465 | $1.67M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 4,420 | 3,774 | $609K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 9,964 | 8,605 | $517K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 24,789 | 19,497 | $475K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1,186 | 1,008 | $388K |
| G0378 | Hospital observation service, per hour | 4,269 | 2,537 | $369K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 18,189 | 14,470 | $335K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6,440 | 5,683 | $303K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 41,423 | 35,495 | $279K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 449 | 382 | $259K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5,021 | 4,373 | $251K |
| 80048 | Basic metabolic panel (calcium, ionized) | 33,490 | 27,721 | $240K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2,510 | 2,129 | $204K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,528 | 1,293 | $201K |
| 71046 | Radiologic examination, chest; 2 views | 6,588 | 5,870 | $198K |
| 87400 | 7,242 | 6,933 | $176K | |
| 71045 | Radiologic examination, chest; single view | 6,803 | 5,912 | $162K |
| 96375 | Therapeutic injection; each additional sequential IV push | 5,377 | 4,628 | $145K |
| J3490 | Unclassified drugs | 71,078 | 38,105 | $132K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2,161 | 1,134 | $127K |
| 84484 | 22,011 | 13,211 | $126K | |
| 80053 | Comprehensive metabolic panel | 15,517 | 12,264 | $117K |
| 36415 | Collection of venous blood by venipuncture | 60,077 | 47,522 | $112K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 13,192 | 12,080 | $98K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1,024 | 935 | $97K |
| 81000 | 28,566 | 25,858 | $96K | |
| 81025 | 12,401 | 11,104 | $92K | |
| 80076 | 13,110 | 11,835 | $85K | |
| A9270 | Non-covered item or service | 45,677 | 23,430 | $59K |
| 83690 | 9,203 | 8,186 | $59K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4,194 | 3,948 | $57K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1,292 | 1,164 | $52K |
| 85027 | 7,895 | 6,039 | $42K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 85 | 78 | $39K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3,206 | 2,285 | $36K |
| 80329 | 748 | 367 | $35K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 828 | 700 | $35K |
| 81001 | 8,825 | 7,350 | $29K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 661 | 629 | $25K |
| 83735 | 4,768 | 3,837 | $20K | |
| 85730 | 5,425 | 4,826 | $20K | |
| 87081 | 3,070 | 2,927 | $20K | |
| 80320 | 605 | 528 | $20K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 487 | 414 | $17K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 512 | 491 | $16K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 7,723 | 6,844 | $16K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 455 | 408 | $14K |
| 85610 | 5,642 | 4,987 | $14K | |
| 82728 | 1,136 | 920 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | 626 | 568 | $12K |
| 83605 | 1,691 | 1,410 | $12K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 106 | 100 | $10K |
| 82550 | 2,840 | 2,512 | $10K | |
| 83880 | 539 | 480 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 6,533 | 5,146 | $9K |
| J1650 | Injection, enoxaparin sodium, 10 mg | 850 | 368 | $8K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 131 | 106 | $8K |
| 83550 | 1,072 | 873 | $8K | |
| 59025 | Fetal non-stress test | 143 | 68 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 258 | 238 | $6K |
| 88304 | 71 | 40 | $6K | |
| 87807 | 454 | 430 | $6K | |
| 97597 | 242 | 159 | $6K | |
| 81003 | 2,171 | 1,771 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 102 | 87 | $4K |
| 84702 | 434 | 402 | $4K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 155 | 104 | $4K |
| 94760 | 1,001 | 881 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 26 | 26 | $4K |
| 87040 | 944 | 484 | $4K | |
| 82607 | 289 | 232 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2,405 | 2,090 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 81 | 64 | $3K |
| 82746 | 263 | 212 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 116 | 38 | $3K |
| 80143 | 987 | 515 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 696 | 624 | $2K |
| 74022 | 53 | 51 | $2K | |
| 87070 | 192 | 173 | $2K | |
| 76830 | Ultrasound, transvaginal | 12 | 12 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 289 | 192 | $2K |
| 83540 | 267 | 251 | $2K | |
| J2704 | Injection, propofol, 10 mg | 574 | 345 | $2K |
| 82150 | 306 | 292 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 40 | 38 | $1K |
| 96376 | 70 | 36 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 229 | 218 | $1K |
| 87186 | 171 | 156 | $1K | |
| 87088 | 136 | 108 | $1K | |
| 80061 | Lipid panel | 100 | 94 | $932.04 |
| 82077 | 1,031 | 498 | $861.57 | |
| 80179 | 749 | 321 | $814.16 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 184 | 104 | $807.82 |
| 83036 | Hemoglobin; glycosylated (A1C) | 120 | 108 | $723.67 |
| 82947 | 284 | 167 | $695.74 | |
| 0598T | 24 | 20 | $693.06 | |
| 84100 | 325 | 246 | $682.03 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 26 | 24 | $643.98 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 26 | 24 | $643.89 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 253 | 197 | $626.21 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 41 | 36 | $550.94 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 16 | 15 | $470.44 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 332 | 250 | $449.95 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 21 | 14 | $392.65 |
| 82784 | 24 | 12 | $367.10 | |
| 85379 | 36 | 36 | $358.20 | |
| 86334 | 17 | 12 | $294.49 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 32 | 13 | $266.11 |
| 86850 | 28 | 26 | $201.05 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 27 | 26 | $192.21 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 169 | 151 | $155.19 |
| 86592 | 30 | 29 | $153.99 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 202 | 149 | $133.91 |
| 86901 | 60 | 55 | $108.64 | |
| 86900 | 60 | 55 | $104.05 | |
| 81005 | 46 | 38 | $103.94 | |
| 83521 | 23 | 12 | $62.55 | |
| 87075 | 19 | 12 | $58.19 | |
| 83615 | 16 | 12 | $56.60 | |
| J2060 | Injection, lorazepam, 2 mg | 24 | 12 | $51.17 |
| J0690 | Injection, cefazolin sodium, 500 mg | 37 | 24 | $43.87 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 60 | 53 | $28.57 |
| 87205 | 19 | 12 | $26.20 | |
| J1815 | Injection, insulin, per 5 units | 27 | 12 | $17.19 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 12 | 12 | $9.01 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 33 | 27 | $3.13 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 16 | 14 | $1.86 |